Xenon Pharmaceuticals Q1 EPS $(1.17) Beats $(1.20) Estimate, Cash, Cash Equivalents And Marketable Securities Of $1.3B Extends Cash Runway Into 2029

Benzinga Newsdesk www.benzinga.com Positive 89.6%